The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis.
Conclusion: For the treatment of anemia in Chinese patients with CKD ND, roxadustat is much more effective than a placebo; moreover, it is cost-effective at conventional WTP thresholds.
PMID: 32249625 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Anemia | China Health | Chronic Kidney Disease | Dialysis | Health Management | Study | Urology & Nephrology